CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE Response to consultation
DATE 2017-06-28
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents

The Canadian Medical Association (CMA) is pleased to provide its comments to allow comment in Health Canada’s Patented Medicines Regulations Consultations. The CMA is the national voice of Canadian physicians. Founded in 1867, the CMA exists to help physicians care for patients. The CMA is a voluntary professional organization representing the majority of Canada’s physicians and supporting 15 provincial and territorial councils and over 70,000 physician members.

In the few contexts of total health expenditures in Canada, it is to be noted in 2016, the cost of drugs is a significant concern to Canadians. In 2016, 14% of prescribed drug spending (1.5 billion) came from the OAP. Older Canadians may experience particularly high costs, with over $1,000 per person per year. The cost of prescription drugs in premenopausal women is nearly double that of men. This analysis of BC’s new drug policy highlights the potential savings of universality coverage for overseas drugs. The threat for an improved model of comprehensively, universal coverage for prescription medicines in Canada

CMA Policybase - Canadian Medical Association